Partial reverse of the TCA cycle is enhanced in Taenia crassiceps experimental neurocysticercosis after in vivo treatment with anthelminthic drugs.
Neurocysticercosis (NCC) is the most common helminthic infection and neglected disease of the central nervous system. It is the leading cause of acquired epilepsy and seizures worldwide. Therefore, to study this important neglected disease, it is important to use experimental models. There is no report in the literature on how the parasite's metabolism reacts to antihelminthic treatment when it is still within the central nervous system of the host. Therefore, the aim of this study was to investigate the energetic metabolism of cysticerci experimentally inoculated in the encephala of BALB/c mice after treatment with low dosages (not sufficient to kill the parasite) of albendazole (ABDZ) and praziquantel (PZQ). BALB/c mice were intracranially inoculated with Taenia crassiceps cysticerci and, after 30 days, received treatment with low dosages of ABDZ and PZQ. After 24 h of treatment, the mice were euthanized, and the cysticerci were removed and analyzed through high-performance liquid chromatography (HPLC) to quantify the organic acids related to the energetic metabolism of the parasite. The partial reverse of the TCA cycle was enhanced by the ABDZ and PZQ treatments both with the higher dosage, as the organic acids of this pathway were significantly increased when compared to the control group and to the other dosages. In conclusion, it was possible to detect the increase of this pathway in the parasites that were exposed to low dosages of ABDZ and PZQ, as it is a mechanism that would amplify the energy production in a hostile environment.
Tropical Pathology and Public Health Institute, Federal University of Goiás, Rua 235 s/n, Setor Universitário, Goiás, 74650-050, Brazil.
Leticia
L
de Almeida Leandro
Carolina Miguel
CM
Fraga
Ruy
R
de Souza Lino
Marina Clare
MC
Vinaud
D015766:Albendazole / Q000627:therapeutic use; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D001921:Brain / Q000469:parasitology; D002851:Chromatography, High Pressure Liquid; D002952:Citric Acid Cycle; D051379:Mice; D008807:Mice, Inbred BALB C; D020019:Neurocysticercosis / Q000188:drug therapy* / Q000469:parasitology; D011223:Praziquantel / Q000627:therapeutic use; D013621:Taenia / Q000187:drug effects / Q000378:metabolism*
D000871:Anthelmintics; D011223:Praziquantel; D015766:Albendazole